Results for acquired haemophilia a translation from English to Maltese

acquired haemophilia
emofilja akkwiżita

haemophilia a
emofilija a

if you have acquired haemophilia
jekk għandek l-emofilja akkwiżita

in patients with acquired haemophilia
f’ pazjenti li għandhom emofilja akkwiżita

paediatric haemophilia a population
popolazzjoni pedjatrika

haemophilia a and b with inhibitors
emofilja a u b bl-inibituri

acquired haemophilia has been reported following use of clopidogrel.
emofilija akkwiżita ġiet irrappurtata wara l-użu ta’ clopidogrel.

haemophilia a (congenital fviii deficiency)
emofilija a (defiċjenza konġenita ta’ fviii)

patients with acquired haemophilia may develop inhibitory antibodies to porcine factor viii.
pazjenti b’emofilja akkwiżita jistgħu jiżviluppaw antikorpi inibitorji għall-fattur viii tal-porċini.

prophylaxis and treatment of bleeding in patients with haemophilia a.
għall-prevenzjoni u l-kura ta’ fsada f’pazjenti b’emofilija a.

usually, treatment for haemophilia a is a life-long treatment.
Ġeneralment, it-trattament għal emofilja a huwa għal tul ħajtek kollha.

haemophilia a or b with inhibitors or expected to have a high anamnestic response
emofilja a jew b bl-inibituri jew mistennija li jkollhom rispons anamnestiku għoli

pharmacokinetic parameter estimates for refacto in previously treated patients with haemophilia a
stimi tal-parametri farmakokinetiċi għal refacto f’pazjenti li kienu kkurati qabel u li għandhom l- emofilja a.

in patients with haemophilia a, factor viii is missing or not working properly.
f’pazjenti b’emofilija a, fattur viii ikun nieqes jew ma jkunx jaħdem kif suppost.

18 pharmacokinetic parameter estimates for refacto in previously treated patients with haemophilia a pk parameter
stimi tal- parametri farmakokinetiċi għal refacto f’ pazjenti li kienu kkurati qabel u li għandhom l - emofilja a.

patients with haemophilia a may develop neutralising antibodies (inhibitors) to factor viii.
pazjenti b’emofilija a jistgħu jiżviluppaw antikorpi li jinnewtralizzaw (inibituri) għall-fattur viii.

obizur is a medicine used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor viii.
obizur huwa mediċina li tintuża għall-kura ta' episodji ta' fsada f'adulti b'emofilja akkwiżita, disturb ta' fsada kkawżat mill-iżvilupp spontanju ta' antikorpi li jiddiżattivaw il-fattur viii.

treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).
kura u profilassi ta’ emorraġiji f’pazjenti b’emofilja a (nuqqas konġenitali tal-fattur viii).

obizur is used for the treatment of bleeding episodes in adults with acquired haemophilia (a bleeding disorder caused by lack of factor viii activity due to antibody development).
obizur jintuża għall-kura ta' episodji ta' fsada f'adulti b'emofilja akkwiżita (disturb bil-fsada kkawżata min-nuqqas ta' attività tal-fattur viii minħabba l-iżvilupp ta' antikorpi).

fviii inhibition: patients with haemophilia a may develop neutralising antibodies (inhibitors) to fviii.
inibizzjoni ta’ fviii: pazjenti b’emofilija a jistgħu jiżviluppaw antikorpi li jinnewtralizzaw (inibituri) għal fviii.